^{Published on 4.6.2026}
Medical device development rarely fails because of one large problem. Delays tend to build through smaller issues that weren't addressed early enough: unclear requirements, missing documentation, late risk management input, or quality expectations that only surface when the project is already moving fast.

For larger medtech companies, this matters beyond project-level inconvenience. When launch schedules, resource allocation and market commitments are affected, the ripple effects create real pressure for business leaders expected to drive innovation, manage costs and maintain compliance across regions, often within complex matrix organisations.

This is where integrated QA/RA support makes a practical difference.

Compliance as a design enabler, not a checkpoint

When quality assurance and regulatory affairs expertise is embedded in development from the start, teams can make decisions with a clearer understanding of regulatory expectations, documentation needs, risk management, and manufacturing requirements while there is still room to act on them.

The regulatory environment reinforces this urgency. In the US, FDA's Quality Management System Regulation came into effect in February 2026, incorporating ISO 13485:2016 as the foundational QMS framework. In the EU, the Medical Device Regulation raises the bar on conformity assessment, clinical evaluation, and post-market surveillance. Design work, documentation, risk management and quality planning need to evolve together, not run in parallel and reconcile at the end.

“Things like the intended clinical benefit must be determined from the very beginning to ensure the design will be built to deliver that intended benefit for its intended users”, Innokas Head of QA/RA Annika Astola brings up. “On top of that, QA/RA and marketing need to share an understanding as well. It’s common to forget that claims on product’s performance and safety in all promotional material must be backed up by clinical evidence”

Reducing rework before it becomes expensive

Many design decisions carry regulatory and quality implications that only become visible later. If QA/RA input arrives near the end of development, the team may find that certain choices require additional justification, testing or documentation, and in the worst case, design changes. That creates internal friction and slows time-to-market.

With integrated support, potential gaps can be identified before development accelerates. Requirements get clarified while they can still shape the design. Verification and validation planning can be built around the intended use and target markets, not added in hindsight.  

"Regular, proactive communication plays a key role here. A QA/RA team that stays closely connected with stakeholders, asks the right questions and continuously aligns expectations can mitigate most issues before they escalate. This reduces uncertainty and helps ensure the final outcome matches both regulatory requirements and customer goals," Annika says.

Extending internal capability without losing control

For many medtech companies, internal QA/RA specialists are stretched across core portfolios, submissions, audits, and post-market activities. When a new development project starts, there may not be enough internal capacity to support it properly.

A development partner with integrated QA/RA services can act as an extension of the customer's team, supporting documentation discipline, risk-based thinking and quality-driven development without taking over strategic ownership. For business leaders evaluating outsourcing options, this means the partner brings technical capacity as well as a structured way to manage quality and regulatory expectations.

Working with organizations with an established quality culture and a strong internal QA/RA team, external experts' focus areas are clearly defined. They adapt to the customer’s operating model and focus on agreed areas such as usability or specific regulatory tasks, and the scope is intentionally limited to complement existing capabilities. If systems and processes are missing, they can be built and developed in collaboration.

Keeping this collaboration effective relies on clear roles and shared understanding. The customer’s own experts bring deep knowledge of the device, internal processes, responsibilities, and business priorities. External QA/RA professionals contribute experience and adaptability from working across multiple organisations and environments. Together, responsibilities are defined based on needs and capabilities, creating a balanced and efficient way of working.

Understanding and adaptability

At Innokas, QA/RA specialists have a strong understanding of the full product development lifecycle as one of its key strengths. The collaboration with engineers ensures that user needs are consistently reflected in design decisions, and that development, documentation and design review processes move forward in alignment.  

QA/RA support is integrated into design and development services to help customers move from idea to implementation in a structured, compliant and practical way and building the quality and regulatory understanding needed for safer, more reliable and market-ready medical devices. This can include, for example, regulatory planning, usability engineering, and risk management as part of a cohesive development approach. If you are looking for something like this, leave a contact form through the link below.